Emily Carter analyzes regulatory, policy, and governance issues influencing biotechnology and medical innovation. Her work examines how regulatory decisions, legal frameworks, and public policy shape research, commercialization, and patient access. At The Catalyst Brief, Emily brings a systems-level perspective, linking policy developments with scientific and market realities.
144 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyMounting evidence gaps in the MENA region are now manifesting as tangible commercial liabilities for pharmaceutical companies. From missed opportunities at the outset of clinical design to downstream business impacts, the issue throws a spotlight on the evolving interplay between regulatory demands and global corporate strategy.
Emily CarterJul 5, 2026
Regulatory & PolicyThe recent attention to hantavirus outbreaks raises urgent questions about whether the United States is building durable preparedness infrastructure or simply improvising from one infectious disease emergency to the next. Examining the lessons from hantavirus, this article explores shortcomings in public health readiness and the perennial dilemma of sustainable epidemic response.
Emily CarterJul 4, 2026
Medical TechnologyWith the FDA awarding breakthrough device designation to Aurenar’s V-Link, a novel ear-based nerve stimulation device, clinicians and patients may soon see a transformative approach to addressing the risks of brain hemorrhage. Results from early trials show a remarkable reduction in cerebral vasospasm, a major complication after a brain bleed, igniting discussions over the future of non-invasive neuroprotection.
Emily CarterJul 3, 2026
Regulatory & PolicyStarting July 1, alterations to federal student loan policy are having profound implications for aspiring healthcare professionals, especially women. As debate intensifies over what kinds of labor—and whose labor—receive public investment, the industry faces a reckoning over gender equity, workforce sustainability, and the future shape of care delivery.
Emily CarterJun 30, 2026
Biopharmaceutical IndustryThe past month saw a notable shuffle of executive leaders and workforce reductions—spanning from medical associations and government bodies to biotech and provider organizations. Beyond the announcements, these shifts raise new questions about organizational resiliency, financial pressures, and the evolving priorities of the healthcare sector.
Emily CarterJun 30, 2026
Biopharmaceutical IndustryHealthcare organizations may excel at meeting the wrong benchmarks, leading to subpar patient experiences and persistent operational challenges. Examining the deeper consequences of a 'good enough' mentality unpacks why high performance should be strategically redefined across the industry.
Emily CarterJun 27, 2026
Biopharmaceutical IndustryThe U.S. Food and Drug Administration's (FDA) decision to convene an advisory committee to evaluate Capricor’s deramiocel—following a prior rejection and silent resubmission process—spotlights ongoing unpredictability in the path to approval for rare disease therapies. This move has significant implications for Capricor and the DMD community, touching on both the regulatory environment and biotech investor sentiment.
Emily CarterJun 27, 2026
AI in Drug DiscoveryAI’s technological prowess in healthcare is evident, but many projects stall once initial pilots end. This deep-dive analysis explores why capability alone is not enough, identifying systemic obstacles and offering context on moving from pilot to practice.
Emily CarterJun 26, 2026
Regulatory & PolicyA new ACIP charter broadens membership criteria and reduces the committee’s responsibility to recommend new vaccines. This substantial policy shift could signal a reframing of U.S. vaccine advisory processes, with implications for expert composition and the CDC’s broader public health strategy.
Emily CarterJun 26, 2026
Regulatory & PolicyA Texas physician is at the center of an alleged $89 million fraud scheme, accused of billing insurance for medically unnecessary cardiovascular screening tests. This high-profile indictment comes as federal regulators pledge intensified crackdown efforts in the health care sector, signaling broader shifts in enforcement and oversight.
Emily CarterJun 23, 2026
Biotech InnovationAs the role of monoclonal antibodies expands in healthcare, nations and health systems are re-evaluating their preventive medicine strategies. The precision, adaptability, and growing uptake of this approach mark a significant departure from historical paradigms.
Emily CarterJun 22, 2026
Regulatory & PolicyThe WISeR model remains a lightning rod in federal healthcare policy discussions, with Congressional Democrats taking steps toward repeal. However, a complex interplay of political, industry, and expert opinions raises questions about whether these efforts can succeed, and what it means for the broader healthcare landscape.
Emily CarterJun 21, 2026